{"sequenceId":"845367131571","id":"34207257715","language":"English","title":"$830,000.00 in Sales Expected for Miragen Therapeutics Inc (MGEN) This Quarter","content":"Brokerages expect that Miragen Therapeutics Inc (NASDAQ:MGEN) will announce sales of $830,000.00 for the current fiscal quarter, according to Zacks . Three analysts have provided estimates for Miragen Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $1.20 million. Miragen Therapeutics reported sales of $720,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 15.3%. The business is expected to announce its next earnings results  on Friday, August 10th.    According to Zacks, analysts expect that Miragen Therapeutics will report full-year sales of $5.76 million for the current financial year, with estimates ranging from $1.50 million to $8.50 million. For the next financial year, analysts expect that the firm will report sales of $3.00 million per share, with estimates ranging from $300,000.00 to $5.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Miragen Therapeutics.    Get Miragen Therapeutics alerts:      Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. The company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%.    A number of equities analysts have recently commented on the stock. Wedbush  reissued an “outperform” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a research note on Friday, May 18th. Zacks Investment Research downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 16th. Cowen  reissued a “hold” rating on shares of Miragen Therapeutics in a research note on Monday, April 9th. Jefferies Group assumed coverage on shares of Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Deutsche Bank assumed coverage on shares of Miragen Therapeutics in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 target price on the stock. One analyst  has rated the stock with a sell rating, two have given a hold rating and eight have issued  a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $16.11.  Shares of Miragen Therapeutics traded up $0.25, reaching $7.32, during mid-day trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 57,430 shares, compared to its average volume of 238,141. Miragen Therapeutics has a 12-month low of $5.01 and a 12-month high of $15.91. The company has a current ratio of 20.91, a quick ratio of 20.91 and a debt-to-equity ratio of 0.14. The company has a market cap of $219.50 million, a PE ratio of -5.30 and a beta of 1.32.    Several hedge funds have recently modified their holdings of MGEN. Citadel Advisors LLC purchased a new position in shares of  Miragen Therapeutics in the 1st quarter valued at $117,000.  Wells Fargo & Company MN grew its holdings in  Miragen Therapeutics by 203.8% during the 4th quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 11,943 shares in the last quarter.  Schwab Charles Investment Management Inc. grew its holdings in  Miragen Therapeutics by 63.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 34,900 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 13,600 shares in the last quarter.  Aveo Capital Partners LLC acquired a new stake in  Miragen Therapeutics during the 4th quarter valued at $279,000.  Finally, Millennium Management LLC acquired a new stake in  Miragen Therapeutics during the 1st quarter valued at $409,000. 33.15% of the stock is currently owned by institutional investors and hedge funds.    About Miragen Therapeutics    Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.    Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","contentWithMarkup":"Brokerages expect that Miragen Therapeutics Inc (NASDAQ:MGEN) will announce sales of $830,000.00 for the current fiscal quarter, according to Zacks . Three analysts have provided estimates for Miragen Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $1.20 million. Miragen Therapeutics reported sales of $720,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 15.3%. The business is expected to announce its next earnings results  on Friday, August 10th.    According to Zacks, analysts expect that Miragen Therapeutics will report full-year sales of $5.76 million for the current financial year, with estimates ranging from $1.50 million to $8.50 million. For the next financial year, analysts expect that the firm will report sales of $3.00 million per share, with estimates ranging from $300,000.00 to $5.50 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Miragen Therapeutics.    Get Miragen Therapeutics alerts:      Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, May 9th. The medical research company reported ($0.18) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. The company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $1.17 million. Miragen Therapeutics had a negative net margin of 290.61% and a negative return on equity of 50.53%.    A number of equities analysts have recently commented on the stock. Wedbush  reissued an “outperform” rating and issued a $19.00 target price on shares of Miragen Therapeutics in a research note on Friday, May 18th. Zacks Investment Research downgraded shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 16th. Cowen  reissued a “hold” rating on shares of Miragen Therapeutics in a research note on Monday, April 9th. Jefferies Group assumed coverage on shares of Miragen Therapeutics in a research note on Thursday, March 29th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, Deutsche Bank assumed coverage on shares of Miragen Therapeutics in a research note on Thursday, March 22nd. They issued a “buy” rating and a $15.00 target price on the stock. One analyst  has rated the stock with a sell rating, two have given a hold rating and eight have issued  a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $16.11.  Shares of Miragen Therapeutics traded up $0.25, reaching $7.32, during mid-day trading on Monday, Marketbeat reports. The company’s stock had a trading volume of 57,430 shares, compared to its average volume of 238,141. Miragen Therapeutics has a 12-month low of $5.01 and a 12-month high of $15.91. The company has a current ratio of 20.91, a quick ratio of 20.91 and a debt-to-equity ratio of 0.14. The company has a market cap of $219.50 million, a PE ratio of -5.30 and a beta of 1.32.    Several hedge funds have recently modified their holdings of MGEN. Citadel Advisors LLC purchased a new position in shares of  Miragen Therapeutics in the 1st quarter valued at $117,000.  Wells Fargo & Company MN grew its holdings in  Miragen Therapeutics by 203.8% during the 4th quarter. Wells Fargo & Company MN now owns 17,804 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 11,943 shares in the last quarter.  Schwab Charles Investment Management Inc. grew its holdings in  Miragen Therapeutics by 63.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 34,900 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 13,600 shares in the last quarter.  Aveo Capital Partners LLC acquired a new stake in  Miragen Therapeutics during the 4th quarter valued at $279,000.  Finally, Millennium Management LLC acquired a new stake in  Miragen Therapeutics during the 1st quarter valued at $409,000. 33.15% of the stock is currently owned by institutional investors and hedge funds.    About Miragen Therapeutics    Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of microRNA-155, which is in Phase I clinical trial for treating cutaneous T-cell lymphoma; MRG-201, a replacement for microRNA-29, which is in Phase I clinical trial that is found at low levels in various pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, and pulmonary fibrosis, as well as systemic sclerosis; and MRG-110, an inhibitor of microRNA-92 that is expressed in endothelial cells and has shown to accelerate the formation of new blood vessels in preclinical models of heart failure, peripheral ischemia, and dermal wounding in the United States and Japan.    Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)    For more information about research offerings from Zacks Investment Research, visit Zacks.com","tags":[],"publishedDate":"2018-06-02T21:54:48Z","harvestDate":"2018-06-02T21:59:17Z","estimatedPublishedDate":"2018-06-02T21:54:48Z","url":"http://ct.moreover.com/?a=34207257715&p=1u0&v=1&x=tCpRVoufksQo4YF0ipcZlw","originalUrl":"https://www.themarketsdaily.com/2018/06/02/830000-00-in-sales-expected-for-miragen-therapeutics-inc-mgen-this-quarter.html","outboundUrls":["https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","https://www.marketbeat.com/","https://www.zacks.com/registration/pfp/?ALERT=zrmodule&ADID=AMERBMN_CONTENT_ZER&skip_rpt_name_check=skip_rpt_name_check&t=MGEN"],"wordCount":"773","dataFormat":"text","duplicateGroupId":"34207257715","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"Miragen Therapeutics Inc","symbol":"1S1N","exchange":"FRA","isin":"US60463E1038","titleCount":1,"contentCount":23,"primary":true},{"name":"Miragen Therapeutics Inc","symbol":"MGEN","exchange":"NAS","isin":"US60463E1038","titleCount":1,"contentCount":23,"primary":true},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"STU","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"BER","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"MUN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"DUS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"FRA","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SWX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"ETR","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCNP","exchange":"PINX","isin":"US9497468879","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"NYS","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"SGO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"MEX","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"LIM","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCO34","exchange":"BSP","isin":"BRWFCOBDR009","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"BUE","isin":"ARDEUT110434","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"NWT","exchange":"HAN","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpV","exchange":"NYS","isin":"US94988U7303","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpR","exchange":"NYS","isin":"US9497464654","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpW","exchange":"NYS","isin":"US94988U7147","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpO","exchange":"NYS","isin":"US9497467210","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpY","exchange":"NYS","isin":"US94988U6560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpN","exchange":"NYS","isin":"US9497467475","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpJ","exchange":"NYS","isin":"US9497468796","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpX","exchange":"NYS","isin":"US94988U6727","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpL","exchange":"NYS","isin":"US9497468044","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpP","exchange":"NYS","isin":"US9497466550","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpT","exchange":"NYS","isin":"US9497463664","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFCpQ","exchange":"NYS","isin":"US9497465560","titleCount":0,"contentCount":2,"primary":false},{"name":"Wells Fargo & Co","symbol":"WFC","exchange":"WBO","isin":"US9497461015","titleCount":0,"contentCount":2,"primary":false},{"name":"Capital Partners SA","symbol":"CPA","exchange":"WAR","isin":"PLCPTLP00015","titleCount":0,"contentCount":1,"primary":false},{"name":"Capital Partners SA","symbol":"0LSM","exchange":"LTS","isin":"PLCPTLP00015","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"FRA","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"HAN","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"MUN","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"DUS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"STU","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"HAM","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"BER","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"SWX","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"ETR","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DB","exchange":"NYS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"BSE","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBN","exchange":"MEX","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"0H7D","exchange":"LTS","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false},{"name":"Deutsche Bank AG","symbol":"DBK","exchange":"MIL","isin":"DE0005140008","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Danessa Lincoln","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Markets Daily","homeUrl":"http://www.themarketsdaily.com","category":"Trade","editorialRank":"3","industry":"Banking & Finance","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"564518075","name":"Markets Daily","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"0"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials"],"genre":"General"}},"es_id":86994652}